Different CAR-NK-EGFR cells showed target-specific cytotoxicity in in vitro cell-based assays, reduced xenograft tumor growth in renal cell carcinoma and triple-negative breast cancer animal models, and significantly extended survival of intracranial tumor-bearing animals in metastatic breast cancer and glioblastoma models (231, 233–236). This evidence concerns the gene EGFR and neoplasm.